| Literature DB >> 34252453 |
Gönül Erkan1, Buket Ozyaprak2, Ferdane Aydoğdu Kaya1, İhsan Dursun3, Levent Korkmaz4.
Abstract
BACKGROUND AND OBJECTIVES: We aimed to investigate the effects of two different anesthetic techniques in our patients who underwent transcatheter aortic valve implantation (TAVI).Entities:
Keywords: Aortic stenosis; General anesthesia; Heart valve prosthesis; Local anesthesia
Mesh:
Substances:
Year: 2021 PMID: 34252453 PMCID: PMC9515671 DOI: 10.1016/j.bjane.2021.06.017
Source DB: PubMed Journal: Braz J Anesthesiol ISSN: 0104-0014
Comparison of patients' demographic and pre-procedural data.
| Local anesthesia (n = 245) | General Anesthesia (n = 58 ) | ||
|---|---|---|---|
| Age (years) | 83 (78.5–86) | 84 (77.7–86.2) | 0.543 |
| Male gender (%) | 104 (42.4) | 26 (44.8) | 0.748 |
| ASA 3 (%) | 197 (80.4) | 40 (68.9) | 0.368 |
| ASA 4 (%) | 48 (19.5) | 18 (31) | 0.123 |
| EF (%) | 60 (50–60) | 55 (40–60) | 0.201 |
| Logistic EuroSCORE | 21 (18–25) | 22 (17.5–25) | 0.661 |
| STS risk score | 12 (8.6–20) | 13.5 (10–17.2) | 0.418 |
| HT (%) | 167 (68.1) | 43 (74.1) | 0.615 |
| DM (%) | 85 (34.6) | 21 (36.2) | 0.906 |
| COPD (%) | 68 (27.7) | 13 (22.4) | 0.396 |
| CVD (%) | 25 (10.2) | 6 (10.3) | 0.944 |
| CRF (%) | 19 ( 7.7) | 5 (8.6) | 0.810 |
| CAD (%) | 154 (62.8) | 36 (62) | 0.929 |
| PAD (%) | 1 (0.4) | 5 (8.6) |
Values are median (interquartile range).
ASA, American Society of Anesthesiologists; EF, Ejection Fraction; DM, Diabetes Mellitus; COPD, Chronic Obstructive Pulmonary Disease; CVD, Cerebrovascular Disease; CRF, Chronic Renal Failure; CAD, Coronary Artery Disease; PAD, Peripheral Artery Disease.
Figure 1Distribution of the anesthesia technique throughout the years.
Comparison of patients' data during the procedure.
| Local anesthesia (n = 245) | General anesthesia (n = 58) | ||
|---|---|---|---|
| Duration of anesthesia (min) | 95 (75–120) | 160 (135–191.25) | |
| Duration of the procedure (min) | 80 (60–110) | 147.5 (120–181.25) | |
| Fluid administered during the procedure (ml) | 760 (650–900) | 1215 (977.5–1705) | |
| Use of blood products (%) | 76 (31,20) | 20 (34.8) | 0.622 |
| Hemodynamic instability (%) | 32 (13.06) | 15 (25.4) | |
| Ephedrine use (%) | 29 (11.8) | 13 (22.4) | 0.086 |
| Inotrope use (%) | 5 (2.0) | 12 (20.6) | |
| Edwards-Sapien valve (%) | 198 (97.1) | 57 (98.2) | 0.943 |
| Medtronic-Core valve (%) | 7 (2.8) | 1 (1.7) | 0.655 |
| Transfemoral approach (%) | 245 (100) | 53 (93.3) | 0.614 |
| Transapical approach (%) | – | 5 (8.6) | – |
Values are median (interquartile range).
Comparison of postoperative data and major complications.
| Local anesthesia (n = 245) | General anesthesia (n = 58) | ||
|---|---|---|---|
| Duration of stay in the intensive care unit (days) | 2 (1–3) | 3.5 (2–6) | |
| Length of hospital stay (days) | 6 (5–7.75) | 7 (5–10) | |
| Pacemaker requirement (%) | 28 (11.4) | 6 (10.3) | 0.827 |
| Arrhythmia (%) | 32 (13) | 7 (12) | 0.841 |
| Vascular complications (%) | 18 (7.3) | 5 (8.6) | 0.617 |
| Infection (%) | 8 (3.2) | 2 (3.4) | 0.806 |
| Neurological dysfunction (%) | 5 (2) | 3 (5.1) | 0.257 |
| Paravalvular leak (%) | 7 (2.8) | 1 (1.7) | 0.101 |
| Myocardial infarction (%) | 3 (1.2) | 2 (3.4) | 0.180 |
| Renal dysfunction (%) | 14 (5.7) | 4 (6.8) | 0.782 |
| 30-day mortality | 19 (7.7) | 5 (8.6) | 0.808 |
Values are median (interquartile range).
Figure 2Distribution of mortality rate throughout the years.